Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
23 Leser
Artikel bewerten:
(0)

Biotechnology Market - Expected to Reach $727 Billion by 2025

DUBLIN, Dec. 27, 2017 /PRNewswire/ --

The "Biotechnology Market Analysis by Application (Health, Food & Agriculture, Natural Resources & Environment, Industrial Processing Bioinformatics), by Technology and Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.

Research and Markets Logo

The global biotechnology market is expected to reach USD 727.1 billion by 2025. The emergence of certain key themes in the biotechnology market is expected to drive growth in this industry to a lucrative extent.

These key themes include regenerative medicine and genetics in diagnostics. Presence of a plethora of companies focusing on the development of regenerative therapies is anticipated to drive sector growth through to 2025. Technological advancements pertaining to the penetration of artificial intelligence in this industry is expected to fuel progress with potential avenues. The companies are engaged in unleashing machine learning in order to understand individual cancer cases, while recommending clinical trials.

Supportive government (and its allied agencies) policies related to synthetic biology is a major growth impacting driver in this sector. Developed economies such as UK and the U.S. are critically monitoring and funding synthetic biology R&D initiatives. For example, in 2010, a six months' review of synthetic biology headed by a panel of expert scientists was enforced by the U.S. President and subsequently conducted a hearing of the Energy and Commerce Committee exclusively concerning synthetic biology.

Further key findings from the report suggest:



  • Owing to technological advancements and widespread application of this field in various aspects of healthcare, the health segment is expected to exhibit strong progress in the forecast period
  • Continuous introduction of new biotechnological products to cater to healthcare entities that are involved in diagnosis, prognosis and biopharmaceutical development is estimated to propel the market
  • Decreasing costs and rise in number of services in this segment are expected to drive segment with lucrative avenues
  • North American pharmaceutical and biotech companies have experienced great success in the recent years resulting in larger share
  • Introduction of technologically advanced products and presence of various biotechnology based programs such as the UC Davis Biotechnology Program, the University of California Biotechnology Research and Education Program are attributive to drive the growth of sector in the coming years
  • Asia Pacific market is anticipated to grow at the most lucrative pace due to changing health care infrastructure in this region which drives the demand for these products
  • Strong governmental support and recruitment of highly trained Chinese scientists with the support of their administration has made it possible for China to speedily build up capacity in area of regenerative medicine

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Biotechnology Market: Variables, Trends & Scope

Chapter 4 Biotechnology Market: Application Estimates & Trend Analysis

Chapter 5 Biotechnology Market: Technology Estimates & Trend Analysis

Chapter 6 Biotechnology Market: Regional Estimates & Trend Analysis, by Application & Technology

Chapter 7 Competitive Landscape

  • Abbott
  • Amgen, Inc.
  • AstraZeneca
  • Biogen
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd
  • Gilead
  • Johnson & Johnson Services, Inc.
  • Lonza
  • Merck & Co
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.
  • Sanofi Aventis

For more information about this report visit https://www.researchandmarkets.com/research/77rljw/biotechnology

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.